<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8</volume><submitter>Devitt J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Indigenous Australians are slightly more than 2% of the total Australian population however, in recent years they have comprised between 6 and 10% of new patients beginning treatment for end-stage kidney disease (ESKD). Although transplant is considered the optimal form of treatment for many ESKD patients there is a pronounced disparity between the rates at which Indigenous ESKD patients receive transplants compared with their non-Indigenous counterparts. The IMPAKT (Improving Access to Kidney Transplants) Interview study investigated reasons for this disparity through a large scale, in-depth interview study involving patients, nephrologists and key decision-making staff at selected Australian transplant and dialysis sites.&lt;h4>Methods&lt;/h4>The design and conduct of the st</pubmed_abstract><journal>BMC health services research</journal><pagination>31</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2275237</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Study Protocol--Improving Access to Kidney Transplants (IMPAKT): a detailed account of a qualitative study investigating barriers to transplant for Australian Indigenous people with end-stage kidney disease.</pubmed_title><pmcid>PMC2275237</pmcid><pubmed_authors>Anderson K</pubmed_authors><pubmed_authors>Devitt J</pubmed_authors><pubmed_authors>Cunningham J</pubmed_authors><pubmed_authors>Preece C</pubmed_authors><pubmed_authors>Snelling P</pubmed_authors><pubmed_authors>Cass A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Study Protocol--Improving Access to Kidney Transplants (IMPAKT): a detailed account of a qualitative study investigating barriers to transplant for Australian Indigenous people with end-stage kidney disease.</name><description>&lt;h4>Background&lt;/h4>Indigenous Australians are slightly more than 2% of the total Australian population however, in recent years they have comprised between 6 and 10% of new patients beginning treatment for end-stage kidney disease (ESKD). Although transplant is considered the optimal form of treatment for many ESKD patients there is a pronounced disparity between the rates at which Indigenous ESKD patients receive transplants compared with their non-Indigenous counterparts. The IMPAKT (Improving Access to Kidney Transplants) Interview study investigated reasons for this disparity through a large scale, in-depth interview study involving patients, nephrologists and key decision-making staff at selected Australian transplant and dialysis sites.&lt;h4>Methods&lt;/h4>The design and conduct of the st</description><dates><release>2008-01-01T00:00:00Z</release><publication>2008 Feb</publication><modification>2025-04-26T05:08:34.325Z</modification><creation>2019-03-27T02:44:33Z</creation></dates><accession>S-EPMC2275237</accession><cross_references><pubmed>18248667</pubmed><doi>10.1186/1472-6963-8-31</doi></cross_references></HashMap>